Table 1.

Objectives.

Objective	Tools	Endpoints
Clinico-genetic stratification of parkinsonism	−Deep clinical phenotyping (motor and non-motor) with annual follow-up −Genotyping (NeuroChip; Blauwendraat et al., 2017) −Investigation of exposure factors −Different disease stages	Disease history under real-world conditions Stratification markers Progression markers Novel disease markers
Differential diagnosis of atypical parkinsonism	−Inclusion of all atypical PD forms −Inclusion of patients with conversion of diagnosis in follow-up of	Conversion markers Differential markers (IPD/atypical PD) Early markers for the development of atypical parkinsonism
Identification of differential cognitive profiles in PD and atypical PD	−Extensive cognitive phenotyping (five cognitive domains) −Investigation of MCI/PDD MDS Level 2 criteria −Tests to investigate cognition in atypical PD forms −Assessment in different languages in a multilingual population −Establishment of population specific normative data	Cognitive markers for PDD and DLB MCI-subtypes MCI-subtypes (executive, visuo-spatial, amnestic dominant vs. multiple domain (Kalbe et al., 2016) Early diagnostic markers for atypical PD forms Risk/protective factors for dementia
Dissection of association between gait disturbances and cognition	−Detailed assessment of gait including sensor based measures [mPower (Trister et al., 2016), instrumental gait analysis (Klucken et al., 2013; Schlachetzki et al., 2017)] −In-depth and a continuous information collection about disease progression −Various aspects of gait can be linked to various cognition factors	Validation of sensor based assessment for future clinical trials Cognitive predictors for gait impairment
Definition of vision as an early disease marker	−Detailed assessment of vision including color discrimination, contrast sensitivity, and facial emotion recognition (Diederich et al., 1998, 2010; Pieri et al., 2000; Hipp et al., 2014)	Vision as an early marker of PD Facial emotion recognition as a marker for PD